News und Analysen

With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the

The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks

Shares of Cigna Group (NYSE: CI) were up 16.6% as of 1:30 p.m. ET Monday after the health insurance giant reportedly called off its potential acquisition Humana and announced a $10 billion buyback

The stock market has been on a tear for more than a month now, and so it's not unreasonable to see major market benchmarks taking a pause coming into a new week. Stock indexes were mostly flat at

Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden

One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the

I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.

In today's video I will look at three

While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great

Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and

Remember Montgomery Ward, Lehman Brothers, and Pan Am? They were all well-known publicly traded companies that paid dividends. And they all went out of business.

Investors who bought those stocks

Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not

As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January

As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that

Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the

These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions.

The pharma giant's latest big

A $5,000 investment may not seem a significant amount to some, but it can generate tremendous returns in the long run. If you were to invest in the S&P 500, which averages an annual return of around

Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster

Many investors have flocked to big pharma stocks throughout the years. And doing so has paid off handsomely with several of those stocks.

AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stand out as

In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored

Are we currently in a bull market? Some argue that we are. In early June, the S&P 500 closed 20% up from its most recent low, which is the technical definition of a bull market. However, equities